SCL Group said Tuesday it has signed a memorandum of understanding (MOU) with Indonesia's national central hospital for cooperation in medical services and diagnostics.
Cipto Mangunkusumo National Central Hospital (RSCM), which signed the agreement, is Indonesia's leading national central hospital. The deal marks the first collaboration between RSCM and a Korean medical institution in the field of diagnostic medicine.
The two organizations agreed to cooperate in precision diagnostics areas including multi-cancer early screening and genetic testing, AI-based early diagnosis solutions, joint use of medical equipment such as magnetic resonance imaging (MRI) and computed tomography (CT), and mid- to long-term overseas business areas such as IT platforms. For SCL Group, the deal is significant as it establishes a bridgehead for expanding Korea's medical system into Southeast Asia.
"Through cooperation with RSCM, we will further strengthen healthcare cooperation between Korea and Indonesia and expand locally tailored medical services," said Lee Kyung-ryul, chairman of SCL Group. "This agreement will serve as a foundation for expanding our medical network beyond Indonesia to Southeast Asia."
SCL Group operates affiliates covering all areas of healthcare, centered on diagnostic testing and health checkups. One of its affiliates, Seegene Medical Foundation, runs K-LAB, a health checkup center, through its local subsidiary in Indonesia. The company plans to expand cooperation with local medical institutions and accelerate the establishment of a Southeast Asian medical network based on this agreement.
"Through cooperation with K-LAB, we will be able to lay a practical foundation for cooperation in precision diagnostics and preventive medicine," said Supriyanto Darmoredjo, director of RSCM. "We hope that medical services and technology exchanges between the two institutions will become more active."
